Pandion Therapeutics

Pandion Therapeutics

Pandion Therapeutics

Developing a new generation of drugs for autoimmune, inflammatory and transplant indications where existing therapeutics fail to provide transformative efficacy
Founded
2017
Raised
$58M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
Undisclosed amount
Undisclosed funding - 2018
JDRF T1D Fund
$58,000,000
Venture capital (Series A) - 2018
Polaris Partners SR One Versant Ventures +2
Team Size
1–10
Employees
Pulse 2.0

Merck (MRK) To Buy Pandion Therapeutics (PAND) In $1.85 Billion Deal

FinSMEs

Pandion Therapeutics Closes $80M Series B Financing

Undisclosed funding
PE HUB

Pandion Therapeutics lands funding